Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers.

Suzanne J ForrestAlyaa Al-IbraheemiDuong DoanAbigail WardCatherine M ClintonJuan PutraR Seth PinchesCigall KadochSusan N ChiSteven G DuBoisPatrick J LeaveyNicole R LeBoeufElizabeth MullenNatalie CollinsAlanna J ChurchKatherine A Janeway

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

A significant proportion of the INI1-negative tumors express PD-L1, and PD-L1 positivity was associated with extracranial tumor site. These results suggest that clinical trials of immune checkpoint inhibitors are warranted in INI1-negative pediatric cancers.

Keyphrases

clinical trial
childhood cancer
randomized controlled trial
copy number
gene expression
phase ii
double blind